RNF43 p.G659fs 通过 PI3K/AKT/mTOR 信号通路和 HLA-E 上调导致 MSI-high 结直肠癌中 NK 细胞功能障碍
RNF43 p.G659fs leads to natural killer cell dysfunction in MSI-high colorectal cancer through PI3K/AKT/mTOR signaling and HLA-E up-regulation.
肿瘤细胞治疗研究
英文原题:GPR116 receptor regulates the antitumor function of NK cells via Gαq/HIF1α/NF-κB signaling pathway as a potential immune checkpoint.
GPR116 receptor regulates the antitumor function of NK cells via Gαq/HIF1α/NF-κB signaling pathway as a potential immune checkpoint.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
我们的数据表明,GPR116 受体对 NK 细胞功能具有负向作用,而下调 NKG2D-CAR-NK92 细胞中的 GPR116 受体可增强抗肿瘤活性,这为提升 CAR NK 细胞的抗肿瘤效率提供了新思路。
NK细胞是先天免疫细胞之一,可保护机体免受癌症起始细胞侵害。据报道,GPR116受体参与炎症和肿瘤过程,但其对NK细胞的作用尚不明确。
我们发现,GPR116敲除小鼠可通过提高肿瘤中NK细胞的比例和功能,有效清除胰腺癌。此外,NK细胞活化后GPR116受体表达下降。与野生型(WT)NK细胞相比,GPR116缺失NK细胞在体内外具有更强的细胞毒性和抗肿瘤活性,并产生更多颗粒酶B(GzmB)和干扰素(IFN)。从机制上看,GPR116受体通过Gαq/HIF-1α/NF-κB信号通路调节NK细胞功能。此外,下调GPR116受体可增强NKG2D-CAR-NK92细胞在体内外对胰腺癌的抗肿瘤活性。
我们的数据表明,GPR116受体对NK细胞功能具有负向影响;在NKG2D-CAR-NK92细胞中下调GPR116可增强抗肿瘤活性,为提高CAR-NK细胞疗法的抗肿瘤效力提供了新思路。
NK cell is one of innate immune cells and can protect the body from cancer-initiating cells. It has been reported that GPR116 receptor is involved in inflammation and tumors. However, the effect of GPR116 receptor on the NK cells remains largely unclear.
We discovered that GPR116 -/- mice could efficiently eliminate pancreatic cancer through enhancing the proportion and function of NK cells in tumor. Moreover, the expression of GPR116 receptor was decreased upon the activation of the NK cells. Besides, GPR116 -/- NK cells showed higher cytotoxicity and antitumor activity in vitro and in vivo by producing more GzmB and IFN than wild-type (WT) NK cells. Mechanistically, GPR116 receptor regulated the function of NK cells via G q/HIF1 /NF- B signaling pathway. Furthermore, downregulation of GPR116 receptor promoted the antitumor activity of NKG2D-CAR-NK92 cells against pancreatic cancer both in vitro and in vivo.
Our data indicated that GPR116 receptor had a negatively effect on NK cell function and downregulation of GPR116 receptor in NKG2D-CAR-NK92 cells could enhance the antitumor activity, which provides a new idea to enhance the antitumor efficiency of CAR NK cell therapy.
MEMBER ACCOUNT
登录成功会直接打开下一页。